Lupin Ltd. Share Price

Lupin Launches Triple-Combination Inhaler for COPD Care

Limited has introduced Formoflo-G MDI in India after receiving approval from the Drug Controller General of India (DCGI). Lupin describes the product as the world's first fixed-dose triple-combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD). Key Product Details Product Name: Formoflo-G MDI Active Ingredients: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate Administration: Fixed-dose inhaler for twice-daily use Purpose: Long-term management of moderate to severe COPD in eligible patients The new product expands Lupin's respiratory medicine portfolio by combining three established therapies in a single inhaler. The launch reflects the company's focus on respiratory-care innovation and addressing evolving treatment needs. Managing Director Nilesh Gupta and India Region Formulations President Rajeev Sibal emphasised the importance of making innovative, quality respiratory treatments available to patients. 📊 Market Focus: Investors will watch product adoption, prescription trends and its potential contribution to Lupin's respiratory business. #Lupin #LupinLimited #PharmaNews #PharmaceuticalSector #COPD #RespiratoryCare #HealthcareInnovation #PharmaStocks #StockMarketNews #IndianStockMarket #NiveshResearch Disclaimer: Investment in securities market are subject to market risks. Read all related documents carefully before investing.

See More

Lupin Introduces Triple-Combination Inhaler for COPD

Pharmaceutical major

Limited has launched Formoflo-G MDI in India following approval from the Drug Controller General of India (DCGI). The company describes it as the world's first fixed-dose triple-combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD). Key Product Highlights Brand: Formoflo-G MDI Combination: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate Dosage: Fixed-dose formulation designed for twice-daily use Indication: Long-term management of moderate to severe COPD in appropriate patients The launch strengthens Lupin’s respiratory-care portfolio by bringing three established medicines together in a single inhaler. The company aims to expand access to differentiated respiratory therapies and address unmet treatment needs. Lupin Managing Director Nilesh Gupta and India Region Formulations President Rajeev Sibal highlighted the launch as an important step in the company's commitment to respiratory-care innovation and improved patient outcomes. Market Focus: Investors may monitor product uptake, prescription demand and the launch's contribution to Lupin's respiratory segment growth. #Lupin #LupinLimited #PharmaNews #PharmaceuticalSector #COPD #RespiratoryCare #HealthcareInnovation #PharmaStocks #StockMarketNews #IndianStockMarket #NiveshResearch Disclaimer: Investment in securities market are subject to market risks. Read all related documents carefully before investing. This content is for informational purposes only and is not a buy or sell recommendation.

See More

Lupin Launches World-First Triple Inhaler for COPD

Lupin shares closed at Rs 1,956.50 on Friday, up about 1%, hovering near its 52-week low of Rs 1,900 even as the company pushes ahead with a steady stream of product launches, the latest a first-of-its-kind respiratory therapy for the Indian market. Lupin launched Formoflo-G MDI in India after getting approval from the Drug Controller General of India, calling it the world's first fixed-dose triple combination metered-dose inhaler for Chronic Obstructive Pulmonary Disease. The inhaler combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate in a single twice-daily device, meant for long-term management of moderate to severe COPD, a condition affecting more than 55 million people in India. Respiratory disease is a large, underserved category in India, and Lupin already ranks second in the country's respiratory therapy segment, per IQVIA data. A genuine first-in-category combination device, rather than a me-too generic, gives Lupin pricing power and a head start before rivals can replicate the fixed-dose formulation, the kind of differentiated launch investors watch closely since it signals R&D payoff rather than just volume-led growth in a commoditised generics market. The stock has ranged between Rs 1,900 and Rs 2,529.50 over the past 52 weeks, with a market capitalisation of around Rs 89,469 crore, trading much closer to its yearly low than its high. Whether launches like this one shift sentiment depends on how quickly Formoflo-G scales and shows up in the respiratory franchise's revenue over coming quarters. Disclosure: Palash Kag, Proprietor, Sarathi Research (SEBI Reg. No. INH000012740). No position held in Lupin. This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Please consult a registered advisor before making investment decisions.

See More

Lupin: Triple-combination inhaler targets COPD demand

### Lupin: Triple-combination inhaler targets COPD demand Lupin Limited (NSE: LUPIN) launched Formoflo-G MDI in India on October 6, 2026, a fixed-dose triple-combination inhaler for chronic obstructive pulmonary disease (COPD). **Why it matters:** The launch expands Lupin’s respiratory portfolio in a chronic disease category where treatment adherence and effective symptom management matter. New products can support domestic prescription growth and strengthen relationships with doctors. **My view:** The opportunity depends on prescription uptake, affordability and repeat demand, not simply the launch announcement. Lupin’s ability to build market share against established therapies will determine the commercial contribution. Investors should also monitor whether domestic growth can complement the company’s international business. **What I’m watching:** Prescription growth, market share, sales contribution and performance of the respiratory portfolio over the next 2–3 quarters. **Stance:** A useful portfolio addition, but commercial traction will determine its financial impact. **Disclosure:** I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security. **Suggested tags:** Equity Research + Fundamental Views + Stock In News

See More

Lupin receives USFDA approval for injectable drug

Lupin Limited

has received approval from the US Food and Drug Administration (USFDA) for its Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, in a single-dose prefilled syringe. Phytonadione, a form of vitamin K1, is used in the management of certain blood-clotting conditions. The approval gives Lupin another product to market in the United States. The commercial opportunity will depend on launch timing, competition, pricing and the company’s ability to secure market share. Regulatory approval is an important milestone, but it does not guarantee a particular level of sales or profitability. What I’m watching: Product launch details, competition in the US market and the contribution from this injectable to Lupin’s future revenue. Stance: Tracking commercialisation and sales potential following regulatory approval. Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing

See More